Graham David Y, Dore Maria Pina
a Department of Medicine , Michael E. DeBakey VA Medical Center and Baylor College of Medicine and Houston , Houston , TX , USA.
b Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica , University of Sassari , Sassari , Italy.
Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065. Epub 2016 May 3.
Helicobacter pylori (H. Pylori) is a leading cause of gastroduodenal disease, including gastric cancer. H. pylori eradication therapies and their efficacy are summarized. A number of current treatment regimens will reliably yield >90% or 95% cure rates with susceptible strains. None has proven to be superior. We show how to predict the efficacy of a regimen in any population provided one knows the prevalence of antibiotic resistance. As with other infectious diseases, therapy should always be susceptibility-based. Susceptibility testing should be demanded. We provide recommendations for empiric therapies when that is the only option and describe how to distinguish studies providing misinformation from those providing reliable and interpretable data. When treated as an infectious disease, high H. pylori cure rates are relatively simple to reliably achieve.
幽门螺杆菌（H. Pylori）是胃十二指肠疾病（包括胃癌）的主要病因。本文总结了幽门螺杆菌根除疗法及其疗效。许多当前的治疗方案对于敏感菌株能够可靠地产生>90%或95%的治愈率。尚无一种方案被证明具有优越性。我们展示了在已知抗生素耐药率的情况下，如何预测任何人群中一种治疗方案的疗效。与其他传染病一样，治疗应始终基于药敏结果。应要求进行药敏试验。当经验性治疗是唯一选择时，我们提供相关建议，并描述如何区分提供错误信息的研究与提供可靠且可解释数据的研究。将幽门螺杆菌作为一种传染病进行治疗时，较高的幽门螺杆菌治愈率相对容易可靠地实现。
